Repligen Co. (NASDAQ:RGEN) Receives Consensus Rating of “Buy” from Analysts

Repligen Co. (NASDAQ:RGEN) has been given an average rating of “Buy” by the eleven research firms that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $106.14.

A number of research firms have recently commented on RGEN. Stifel Nicolaus began coverage on Repligen in a research report on Thursday, November 14th. They set a “buy” rating and a $105.00 price target on the stock. BidaskClub raised Repligen from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. First Analysis raised Repligen from an “outperform” rating to a “strong-buy” rating and raised their price target for the stock from $107.00 to $110.00 in a research report on Friday, November 1st. Svb Leerink reaffirmed an “outperform” rating and set a $100.00 price target on shares of Repligen in a research report on Tuesday, October 15th. Finally, Leerink Swann began coverage on Repligen in a research report on Tuesday, October 15th. They set an “outperform” rating and a $100.00 price target on the stock.

Shares of NASDAQ RGEN traded up $1.88 during mid-day trading on Tuesday, reaching $90.30. 386,275 shares of the company’s stock were exchanged, compared to its average volume of 366,663. The firm has a market capitalization of $4.60 billion, a price-to-earnings ratio of 123.70, a PEG ratio of 4.34 and a beta of 1.15. The company has a current ratio of 16.03, a quick ratio of 14.70 and a debt-to-equity ratio of 0.25. The business has a fifty day simple moving average of $83.47 and a 200 day simple moving average of $83.07. Repligen has a twelve month low of $48.26 and a twelve month high of $99.25.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, October 31st. The biotechnology company reported $0.26 EPS for the quarter, topping the Zacks’ consensus estimate of $0.19 by $0.07. The company had revenue of $69.45 million for the quarter, compared to analyst estimates of $66.10 million. Repligen had a return on equity of 6.50% and a net margin of 9.28%. Repligen’s revenue was up 40.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.20 earnings per share. Equities research analysts predict that Repligen will post 1.03 earnings per share for the current fiscal year.

In related news, CEO Anthony Hunt sold 12,094 shares of Repligen stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $82.40, for a total value of $996,545.60. Following the sale, the chief executive officer now owns 210,976 shares of the company’s stock, valued at approximately $17,384,422.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.70% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in RGEN. Advisors Preferred LLC acquired a new stake in Repligen in the 2nd quarter valued at approximately $39,000. Benjamin F. Edwards & Company Inc. grew its stake in Repligen by 94.2% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 639 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 310 shares in the last quarter. C M Bidwell & Associates Ltd. bought a new position in Repligen in the second quarter valued at approximately $84,000. Ropes Wealth Advisors LLC bought a new position in Repligen in the second quarter valued at approximately $116,000. Finally, Centaurus Financial Inc. bought a new position in Repligen in the second quarter valued at approximately $129,000. 85.54% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Recommended Story: Insider Trading

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.